Hematologic Oncology | Specialty

Luspatercept Reduces Blood Transfusion Dependence in Lower-Risk MDS Anemia

December 2nd 2018

Treatment with luspatercept significantly reduced the need for frequent red blood cell transfusions in nearly 53% of patients with anemia associated with low- to intermediate-risk myelodysplastic syndrome.

Reduced Treatment Equally Effective in DLBCL

December 2nd 2018

Treating younger patients with low-risk diffuse large B-cell lymphoma with 2 fewer frontline cycles of R-CHOP greatly reduced toxicity without sacrificing efficacy, according to findings from the FLYER trial.

Tisagenlecleucel Benefit Sustained in DLBCL Follow-Up

December 2nd 2018

Tisagenlecleucel continued to demonstrate durable objective response rates with a median of 19 months of follow-up for patients with relapsed or refractory diffuse large B-cell lymphoma, according to updated findings from the phase II JULIET study.

Tisagenlecleucel OS, RFS Sustained in Long-Term Follow-Up for Pediatric ALL

December 2nd 2018

Treatment with the CD19-targeted CAR T-cell therapy tisagenlecleucel demonstrated sustained rates of relapse-free survival and overall survival at 24 and 18 months for pediatric and young adult patients with relapsed or refractory acute lymphoblastic leukemia.

Ibrutinib Established as Standard for Older CLL Patients

December 2nd 2018

Ibrutinib as monotherapy and combined with rituximab significantly improved progression-free survival compared with bendamustine plus rituximab as frontline therapy for older patients with chronic lymphocytic leukemia.

ASH 2018: Dr. O'Connor Shares Insight on MCL and T-Cell Lymphoma Advances

December 1st 2018

ASH 2018: Dr. Wierda Discusses Pivotal Updates in CLL

December 1st 2018

ASH 2018: Dr. Landgren Highlights Pivotal Myeloma Data

December 1st 2018

Dr. Mesa Discusses Exciting Abstracts on Myeloproliferative Neoplasms

December 1st 2018

Dr. Pagel Highlights the Top Abstracts From the 2018 ASH Annual Meeting

December 1st 2018

Dr. Raje Discusses Investigational Treatment Strategies in Multiple Myeloma

December 1st 2018

Dr. Desai Discusses Advances in Treatment for Patients With AML

December 1st 2018

OncLive News Network On Location: In San Diego Monday, December 3

December 1st 2018

OncLive News Network On Location: In San Diego Sunday, December 2

December 1st 2018

OncLive News Network On Location: In San Diego Saturday, December 1

December 1st 2018

New Hairy Cell Leukemia Therapy Aims to Produce Complete Remissions

November 30th 2018

Robert J. Kreitman, MD, discusses key attributes of moxetumomab pasudotox and its potential impact in hairy cell leukemia.

Dr. Jagannath on the Importance of Biology in Multiple Myeloma

November 29th 2018

Sundar Jagannath, MD, director of the Multiple Myeloma program and professor of medicine at the Tisch Cancer Institute, Mount Sinai Health System, discusses the importance of biology in multiple myeloma.

Dr. Komrokji Discusses the FDA Approval of Gilteritinib for FLT3+ AML

November 29th 2018

Rami S. Komrokji, MD, principal investigator, MDS Research Consortium, Aplastic Anemia and MDS International Foundation, clinical director, Hematologic Malignancies, Moffitt Cancer Center, discusses the FDA approval of gilteritinib (Xospata) for the treatment of adult patients with FLT3 mutation–positive relapsed or refractory acute myeloid leukemia.

FDA Approves Gilteritinib for FLT3+ AML

November 29th 2018

The FDA has approved gilteritinib for the treatment of adult patients with FLT3 mutation–positive relapsed or refractory acute myeloid leukemia.

Emerging Agents Propel Progress in MPN Paradigm

November 27th 2018

Stephen Oh, MD, PhD, discusses the use of ruxolitinib in patients with myelofibrosis and polycythemia vera, and emerging agents and next steps in the field of myeloproliferative neoplasms.